Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $15000.0.

  • Ovid Therapeutics' Cash from Financing Activities fell 6052.63% to $15000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $28000.0, marking a year-over-year decrease of 9990.87%. This contributed to the annual value of $622000.0 for FY2024, which is 9796.3% down from last year.
  • Per Ovid Therapeutics' latest filing, its Cash from Financing Activities stood at $15000.0 for Q3 2025, which was down 6052.63% from $13000.0 recorded in Q1 2025.
  • Over the past 5 years, Ovid Therapeutics' Cash from Financing Activities peaked at $30.0 million during Q4 2023, and registered a low of -$43599.0 during Q4 2022.
  • For the 5-year period, Ovid Therapeutics' Cash from Financing Activities averaged around $1.9 million, with its median value being $109549.0 (2022).
  • As far as peak fluctuations go, Ovid Therapeutics' Cash from Financing Activities tumbled by 13993.31% in 2022, and later surged by 6898460.74% in 2023.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Cash from Financing Activities stood at $109180.0 in 2021, then crashed by 139.93% to -$43599.0 in 2022, then skyrocketed by 68984.61% to $30.0 million in 2023, then tumbled by 99.87% to $38000.0 in 2024, then plummeted by 60.53% to $15000.0 in 2025.
  • Its Cash from Financing Activities was $15000.0 in Q3 2025, compared to $13000.0 in Q1 2025 and $38000.0 in Q3 2024.